Septerna is a biochemical drug discovery company. With GPCR scientists, Septerna is focused on researching G protein receptors to develop new medicines in the pharmacology field. The company also features drug-screening technology, modular assemblies, and Silico molecule screening. Septerna was founded by Arthur Christopoulos, Jeffrey Finer, Patrick Sexton, and Robert Lefkowitz in 2022 and is headquartered in San Francisco, CA.

Register for Details

For more details on financing and valuation of private companies similar to Septerna before its IPO, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Septerna

To invest in Septerna pre-IPO

Can you invest in Septerna pre-IPO?

You may invest in Septerna as it is a public company listed on the NASDAQ with ticker SEPN. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of Septerna before it goes public?

You can no longer sell shares of Septerna on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my Septerna shares?

Forge can no longer determine the value of Septerna shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is Septerna a publicly traded company?

Septerna became a public company following its IPO on 10/25/2024 and is now traded on the NASDAQ under the ticker SEPN.

To learn more about Septerna potential IPO

Will Septerna go IPO?

Septerna became a public company following its IPO on 10/25/2024 and is now traded on the NASDAQ under the ticker SEPN.

What is Septerna’s IPO price?

The IPO price of Septerna is not currently available.

When was Septerna founded?

Septerna was founded in 2022.

What is Septerna funding to date?

Septerna has raised $225MM to date.

Who are Septerna’s major investors?

Casdin Capital
Deep Track Capital
Bvf Partners
Invus
Vertex Ventures
Goldman Sachs Asset Management
Soleus Capital
Catalio Capital Management
Samsara Biocapital
Invus Financial Advisors
Woodline Partners Lp
Driehaus Capital
Vertex Ventures Hc
Ra Capital Management
Mirae Asset Global Investments
Third Rock Ventures
Logos Capital
Woodline Partners
Direhaus Capital Management
Mirae Asset Financial Group

Septerna Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
07/11/2023 Series B $150MM $xx.xx $313.42MM RA Capital Management, Third Rock Ventures, Samsara BioCapital, Invus, Catalio Capital Management, BVF Partners, Casdin Capital, Logos Capital, Deep Track Capital, Goldman Sachs Asset Management, Vertex Ventures HC, Mirae Asset Financial Group, Direhaus Capital Management, Woodline Partners LP, Soleus Capital
Price per Share
$xx.xx
Shares Outstanding
121,657,452
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
RA Capital Management, Third Rock Ventures, Samsara BioCapital, Invus, Catalio Capital Management, BVF Partners, Casdin Capital, Logos Capital, Deep Track Capital, Goldman Sachs Asset Management, Vertex Ventures HC, Mirae Asset Financial Group, Direhaus Capital Management, Woodline Partners LP, Soleus Capital
01/27/2022 Series A $75MM $xx.xx $150MM Third Rock Ventures, Samsara BioCapital, BVF Partners, Invus Financial Advisors, Catalio Capital Management, Casdin Capital, Logos Capital
Price per Share
$xx.xx
Shares Outstanding
75,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Third Rock Ventures, Samsara BioCapital, BVF Partners, Invus Financial Advisors, Catalio Capital Management, Casdin Capital, Logos Capital
Updated on: Nov 17, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.